Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911859 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
NCT00911859 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 118 participants.
The verdict
NCT00911859, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple myeloma (a type of cancer that affects the blood and bone marrow).
Interventions
- DRUG Melphalan
- DRUG Siltuximab11 mg/kg
- DRUG Siltuximab 8.3 mg/kg or 11 mg/kg
- DRUG Velcade (bortezomib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00911859
The ClinicalTrials.gov registry entry for NCT00911859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT00911859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00911859 about?
NCT00911859 is a clinical study titled "A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients". The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple myeloma (a type of cancer that affects the blood and bone marrow).
What is the current status of trial NCT00911859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2009-06. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00911859?
The interventions under investigation include: Melphalan (DRUG), Siltuximab11 mg/kg (DRUG), Siltuximab 8.3 mg/kg or 11 mg/kg (DRUG), Velcade (bortezomib) (DRUG).
Who is sponsoring clinical trial NCT00911859?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.